中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

15 records (took 0.031 seconds)

    Aza- indolyl derivatives for treating obesity
    7.
    发明授权
    Aza- indolyl derivatives for treating obesity 失效
    用于治疗肥胖症的氮杂吲哚基衍生物

    公开(公告)号：US06583134B2

    公开(公告)日：2003-06-24

    申请号：US09794491

    申请日：2001-02-27

    Applicant: Jonathan Mark Bentley ,  Paul Hebeisen ,  Sven Taylor

    Inventor： Jonathan Mark Bentley ,  Paul Hebeisen ,  Sven Taylor

    IPC: A61K3155

    CPC classification number: C07D471/14 ,  C07D487/14

    Abstract: Novel compounds of formula (I): wherein X1, X2, X3 and X4, n, R1, R2 and R3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.

    Abstract translation: 式（I）的新型化合物：其中X 1，X 2，X 3和X 4，n，R 1，R 2和R 3在说明书中定义，并且式（I）化合物的药学上可接受的盐和前药具有治疗用途。 这些化合物可用于治疗中枢神经系统疾病; 损害中枢神经系统; 心血管疾病; 胃肠道疾病; 尿崩症和睡眠呼吸暂停。 它们对治疗肥胖特别有用。

    Indazole derivatives with 5-HT2 receptor activity
    9.
    发明授权
    Indazole derivatives with 5-HT2 receptor activity 失效
    具有5-HT2受体活性的吲唑衍生物

    公开(公告)号：US06552062B1

    公开(公告)日：2003-04-22

    申请号：US09763886

    申请日：2001-02-28

    Applicant: David Reginald Adams ,  Jonathan Mark Bentley ,  Jonathan Richard Anthony Roffey ,  Richard John Hamlyn ,  Ashley Roger George

    Inventor： David Reginald Adams ,  Jonathan Mark Bentley ,  Jonathan Richard Anthony Roffey ,  Richard John Hamlyn ,  Ashley Roger George

    IPC: A61K31416

    CPC classification number: C07D231/56

    Abstract: A chemical compound of formula (I) wherein R1 to R3 are independently selected from hydrogen and alkyl; R4 to R7 are independently selected from hydrogen, halogen, hydroxy, alkyl, aryl, amino, monoalkylamino, dialkylamino, alkoxy, aryloxy, alkylthio, arylthio, arylsulfoxyl, arylsulfonyl, alkylsulfoxyl, alkylsulfonyl, nitro, cyano, carboxaldehyde, alkylcarbonyl, arylcarbonyl, aminocarbonyl, monoalkylaminocarbonyl, dialkylaminocarbonyl, alkoxycarbonylamino, aminocarbonyloxy, monoalkylaminocarbonyloxy, dialkylaminocarbonyloxy, monoalkylaminocarbonylamino and dialkylaminocarbonylamino; and R8 is selected from alkyl and alkoxy, and pharmaceutically acceptable salts and prodrugs thereof, and the use thereof in therapy, particularly for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and particularly for the treatment of obesity.

    Abstract translation: 式（I）的化合物，其中R 1至R 3独立地选自氢和烷基; R4至R7独立地选自氢，卤素，羟基，烷基，芳基，氨基，单烷基氨基，二烷基氨基，烷氧基，芳氧基，烷硫基，芳硫基，芳基亚砜基，芳基磺酰基，烷基亚砜基，烷基磺酰基，硝基，氰基，甲醛，烷基羰基，芳基羰基，氨基羰基 单烷基氨基羰基，二烷基氨基羰基，烷氧基羰基氨基，氨基羰基氧基，单烷基氨基羰基氧基，二烷基氨基羰基氧基，单烷基氨基羰基氨基和二烷基氨基羰基氨基; 并且R 8选自烷基和烷氧基及其药学上可接受的盐和前药，及其在治疗中的用途，特别是用于治疗中枢神经系统疾病的用途; 损害中枢神经系统; 心血管疾病; 胃肠道疾病; 尿崩症和睡眠呼吸暂停，特别是用于治疗肥胖。

Patent Agency Ranking